رئة مربي الطيور غير الليفية: ماذا تفعل عندما لم يُحسّن تجنب المستضد وظائف الرئة

References

Recently published international diagnostic guidelines recommend HP classification into fibrotic or nonfibrotic phenotypes based on the presence or absence of radiological and/or histopathological fibrosis, supported by the observation that pulmonary fibrosis conveys important prognostic and treatment implications.

Moderate-to-high dose systemic corticosteroids would usually be considered for HP patients with features of inflammation (e.g., GGO on HRCT, BAL lymphocytosis, well-documented exposure with acute or sub-acute symptom onset).

For rapid onset pneumonitis with severe physiologic compromise, induction therapy may comprise of pulsed-dose intravenous methylprednisolone, followed by high-dose oral corticosteroids and often steroid-sparing agents (see below).

Following corticosteroid initiation, timely re-evaluation (e.g., between 6 and 12 weeks) is important to ensure improvement or stabilization in clinical symptoms and lung function, and to manage steroid-related side effects.